Pneumococcal conjugate second or third-dose vaccines (PCVc) in Guatemala
Guatemala: Pneumococcal conjugate second or third-dose vaccines (PCVc) was 85.0% in 2025. ◆ Volatile
Latest (2025)
85.0%
Change on year
down 7.6%
World rank
96th
of 194 countries
All-time high
94.0%
in 2023
All-time low
0.0%
in 2008
Years of data
18
2008–2025
Pneumococcal conjugate second or third-dose vaccines (PCVc) in Guatemala, 2008–2025
Source: World Health Organization, Global Health Observatory.
Analysis
Guatemala recorded 85.0% for pneumococcal conjugate second or third-dose vaccines (pcvc) in 2025.
The figure is down 7.6% on the previous year and up 6.2% over ten years.
Over the whole period, pneumococcal conjugate second or third-dose vaccines (pcvc) in Guatemala peaked at 94.0% in 2023 and was at its lowest, 0.0%, in 2008.
Guatemala ranks 96th of 194 countries on this measure, in the middle of the range.
The series is highly variable year to year, so single readings are best treated with caution.
Pneumococcal conjugate second or third-dose vaccines (PCVc) in Guatemala, year by year
| Year | Value | Change |
|---|---|---|
| 2008 | 0.0% | — |
| 2009 | 0.0% | — |
| 2010 | 0.0% | — |
| 2011 | 0.0% | — |
| 2012 | 0.0% | — |
| 2013 | 72.0% | — |
| 2014 | 62.0% | -13.9% |
| 2015 | 80.0% | +29.0% |
| 2016 | 90.0% | +12.5% |
| 2017 | 93.0% | +3.3% |
| 2018 | 90.0% | -3.2% |
| 2019 | 92.0% | +2.2% |
| 2020 | 87.0% | -5.4% |
| 2021 | 79.0% | -9.2% |
| 2022 | 89.0% | +12.7% |
| 2023 | 94.0% | +5.6% |
| 2024 | 92.0% | -2.1% |
| 2025 | 85.0% | -7.6% |
Guatemala compared with similar countries
- Guatemala's 85.0% is above the median for upper middle income countries, which is 76.0%, 1.1× the median. (57 countries reporting)
- Guatemala's 85.0% is above the median for Latin America & Caribbean, which is 82.5%, 1.0× the median. (32 countries reporting)
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 2000s | 0.0% | 0.0% | 0.0% | 2 |
| 2010s | 57.9% | 0.0% | 93.0% | 10 |
| 2020s | 87.7% | 79.0% | 94.0% | 6 |
Countries ranked near Guatemala
More health data for Guatemala
- Un projection of annual infant deaths, annual growth rate -1.92 % change on previous year (2100)
- Heat deaths vs projected death rates, annual growth rate 0.7968 % change on previous year (2090)
- Estimated changes in temperature-related death rates compared to projected death rates 1,202 deaths per 1,000 people (2090)
- Number of infants who die before age 1 1,022 deaths (2100)
- Neonatal tetanus - number of reported cases, gaps filled 0 (2025)
- Population ages 00-04, female, annual growth rate -0.4059 % change on previous year (2025)
- Population ages 00-04, female, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 00-04, female, per capita 0.0487 units per person (2025)
- Population ages 00-04, male, annual growth rate -0.3488 % change on previous year (2025)
- Population ages 00-04, male, per unit of GDP 0 units per US$ of GDP (2025)
Frequently asked questions
- What is pneumococcal conjugate second or third-dose vaccines (pcvc) in Guatemala?
- Pneumococcal conjugate second or third-dose vaccines (pcvc) in Guatemala was 85.0% in 2025, according to World Health Organization, Global Health Observatory.
- What is the highest pneumococcal conjugate second or third-dose vaccines (pcvc) recorded in Guatemala?
- The highest recorded value was 94.0% in 2023.
- What is the lowest pneumococcal conjugate second or third-dose vaccines (pcvc) recorded in Guatemala?
- The lowest recorded value was 0.0% in 2008.
- How does Guatemala rank for pneumococcal conjugate second or third-dose vaccines (pcvc)?
- Guatemala ranks 96th out of 194 countries with data for 2025.
- Is pneumococcal conjugate second or third-dose vaccines (pcvc) rising or falling in Guatemala?
- Over the last ten years it is up 6.2%. The long-run trend across the full record is volatile.
- Where does this Guatemala data come from?
- The figures come from World Health Organization, Global Health Observatory, published as part of Pneumococcal conjugate second or third-dose vaccines (PCVc) immunization coverage by the locally recommended age (%) (WUENIC). Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 18 observations, free to reuse under CC BY-NC-SA 3.0 IGO (WHO).